Harding, James J. http://orcid.org/0000-0002-7029-4310
Piha-Paul, Sarina A.
Shah, Ronak H. http://orcid.org/0000-0001-9042-6213
Murphy, Jessica J.
Cleary, James M.
Shapiro, Geoffrey I. http://orcid.org/0000-0002-3331-4095
Quinn, David I. http://orcid.org/0000-0002-1411-0417
Braña, Irene
Moreno, Victor http://orcid.org/0000-0001-6099-4236
Borad, Mitesh
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Spanggaard, Iben http://orcid.org/0000-0001-5925-2630
Park, Haeseong
Ford, James M. http://orcid.org/0000-0002-2513-7025
Arnedos, Mónica
Stemmer, Salomon M.
de la Fouchardiere, Christelle http://orcid.org/0000-0003-2291-5693
Fountzilas, Christos http://orcid.org/0000-0003-3837-5644
Zhang, Jie
DiPrimeo, Daniel
Savin, Casey
Duygu Selcuklu, S.
Berger, Michael F.
Eli, Lisa D.
Meric-Bernstam, Funda http://orcid.org/0000-0001-6816-6072
Jhaveri, Komal
Solit, David B. http://orcid.org/0000-0002-6614-802X
Abou-Alfa, Ghassan K.
Article History
Received: 20 April 2022
Accepted: 30 January 2023
First Online: 6 February 2023
Competing interests
: J.J.H. has received institutional research support from Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Calithera, Eli Lilly, Genoscience, Incyte, Loxo, Novartis, Pfizer, Yiviva, and Zymeworks and has consulted for Adaptimmune, Bristol Myers Squibb, CytomX, Eisai, Eli Lilly, Exelixis, Merck, QED, and Zymeworks. S.A.P.-P.: has received clinical trial support (to institution) from AbbVie, Inc., ABM Therapeutics, Inc., Acepodia, Inc., Alkermes, Aminex Therapeutics, Amphivena Therapeutics, Inc., BioMarin Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squib, Cerulean Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Curis, Inc., Cyclacel Pharmaceuticals, Daiichi Sankyo, Inc., Eli Lilly, ENB Therapeutics, Five Prime Therapeutics, F-Star Beta Limited, F-Star Therapeutics, Limited, Gene Quantum, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp., HiberCell, Inc., Immunomedics, Inc., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd., Lytix Biopharma AS, Medimmune, LLC., Medivation, Inc., Merck Sharp and Dohme Corp., Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer, Principia Biopharma, Inc., Puma Biotechnology, Inc., Rapt Therapeutics, Inc., Seattle Genetics, Silverback Therapeutics, Synlogic Therapeutics, Taiho Oncology, Tesaro, Inc., and TransThera Bio, and research grant NCI/NIH P30CA016672 – Core Grant (CCSG Shared Resources). R.H.S.: no conflicts declared. J.J.M.: no conflicts declared. JMC: has received research support from Merck, AstraZeneca, Esperas, Tesaro, and Bayer, and payments or honoraria from Syros and Blueprint. G.I.S.: has received research funding from Eli Lilly, Merck KGaA/EMD Serono, Merck, and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Merck KGaA/EMD Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis, CytomX Therapeutics, Blueprint Medicines, Kymera Therapeutics, Janssen and Xinthera. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell. DIQ: has received institutional research support from Merck Sharp and Dohme, Pfizer, Genentech, and Millennium and has consulted for Astellas, Aveo, BMS, Bayer, Genentech/Roche, EMD Serono, Merck Sharp and Dohme, Pfizer and Seagen, received payments or honoraria from Astellas, Aveo, BMS, Bayer, Genentech/Roche, EMD Serono, Merck Sharp and Dohme, Pfizer and Seagen, undertaken data safety monitoring for Eisai and US Biotest, and has employment with AbbVie. I.B.: has received research funding from Puma Biotechnology Inc for the manuscript (to institution), a personal grant from the Spanish National Health Institute, research funding from Institut Salud Carlos III (personal grant Rio Hortega Contract - CM15/00255) and La Caixa Foundation Institutional grant LCF/PR/CEO7/50610001, research funding from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Gliknik, Incyte, ISA Pharmaceuticals, Janssen Oncology, Kura, Merck Serono, Merck Sharp & Dohme, Novartis, Northern Biologics, Orion Pharma, Regeneron, Seattle Genetics, Shattuck Labs, and VCN Biosciences (all institutional research funding to the principal investigator), personal consulting fees from Achilles Therapeutics, Cancer expert Now, eTheRNA Immunotherapies, Merck Sharp & Dohme, and Rakuten Pharma, payments or honoraria from Bristol Myers Squibb, Merck Serono, and Merck Sharp & Dohme (personal fees), support for attending meetings from Merck Serono, and Merck Sharp & Dohme (personal fees), and is an advisory board member of the ESMO Head and Neck Tract, EORTC Head and Neck Group, and Cancer Core Europe Clinical Taskforce. VM: research funding to institution from AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer BeiGene BioInvent International AB, BMS, Boehringer, Boston, Celgene, Daiichi Sankyo, DEBIOPHARM, Eisai, e-Terapeutics, Exelixis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, Pharma Mar, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Rigontec, Roche, Sanofi, Sierra Oncology, Sponsor, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics, and Upsher-Smith Laboratories, and personal consulting fees from Roche, Bayer, Janssen, and Basliea. M.B.: reports grants from Adaptimmune, grants from Senhwa Pharmaceuticals, grants from Agios Pharmaceuticals, personal fees from Merck, grants from EMD Serono, grants from Halozyme, grants from Celgene, grants from Toray, grants from Dicerna, grants from Taiho, grants from Sun Biopharma, grants from Isis Pharmaceuticals, grants from Redhill Pharmaceuticals, grants from Boston Biomed, grants from Basilea, grants from Incyte Pharmaceuticals, grants from Mirna Pharmaceuticals, grants from Medimmune, grants from Bioline, grants from Sillajen, grants from ARIAD, grants from Puma Pharmaceuticals, grants from QED, grants from Novartis Pharmaceuticals, personal fees from ADC Therapeutics, personal fees from Exelixis, personal fees from Inspyr, personal fees from G1 Therapeutics, personal fees from Immunovative, personal fees from OncBioMune, personal fees from Western Oncolytics, personal fees from Lynx Group, personal fees from Genentech, personal fees from HUYA, grants from AstraZeneca, outside the submitted work. S.L.: receives research funding to her institution from Novartis, Bristol Myers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, Roche-Genentech and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, Puma Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Amunix, Tallac Therapeutics, Eli Lilly and Bristol Myers Squibb. I.S.: has received research support (to institution) from Puma Biotechnology, Roche/Genentech, AstraZeneca, Incyte, Pfizer, Orion Pharma, MSD, Bristol Myers Squibb, Novartis, Loxo Oncology, Amgen, and Genmab, and support for travel and attending meetings from Roche and Novartis. H.P.: writing support for the manuscript from Puma Biotechnology Inc, research grant UM1 CA186689, research support to institution from Adlai Nortye USA, Alpine Immune Sciences, Ambrx, Amgen, Aprea Therapeutics AB, Array BioPharma, Bayer, BeiGene, BJ Bioscience, Bristol Myers Squibb, Daiichi Pharmaceutical, Eli Lilly, Elicio Therapeutics, EMD Serono, Exelixis, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Hoffmann-LaRoche, Hutchison MediPharma, ImmuneOncia Therapeutics, Incyte, Jounce Therapeutics, Mabspace Biosciences, MacroGenics, Medimmune, Medivation, MERCK, Millennium, Mirati Therapeutics, Novartis Pharmaceuticals, Oncologie, Pfizer, PsiOxus Therapeutics, Puma Biotechnology, Regeneron, Pharmaceuticals, RePare Therapeutics, Seattle Genetics, Synermore Biologics, Taiho Pharmaceutical, TopAlliance Biosciences, Turning Point Therapeutics, Vedanta Biosciences, Xencor Inc, honorarium from Medscape, and support for attending meetings from Daiichi Sankyo and Vedanta. JMF: has received research funding from Puma Biotechnology Inc for the manuscript (to institution), and research support from Pfizer, Genentech, Merus, Incyte, and AstraZeneca (all to institution). M.A.: has received research funding from Puma Biotechnology Inc for the manuscript (to institution), research funding from Eli Lilly (to institution), consulting fees from AbbVie (to self), payments or honoraria from Pfizer (to self), Roche (to institution), and AstraZeneca (to institution), and support for attending meetings from Pfizer and AstraZeneca (to self). S.M.S.: has received research funding from Puma Biotechnology, Inc. CdelaF: has received grants or contracts from Pierre Fabre Oncologie; payments or honoraria from Amgen, Bayer, Eisai, Servier, Ipsen, and Lilly; payments for expert testimony from Incyte, MSD, Pierre Fabre Oncologie, Ipsen, Roche, and Daiichi Sankyo; support for attending meetings and/or travel from Amgen, Roche, MSD, and Merck. C.F.: has received research funding from Puma Biotechnology Inc for the manuscript (to institution), research funding from the National Comprehensive Cancer Network Oncology Research Program, Taiho Oncology, and Pfizer Inc (all to institution), and equipment, materials, drugs, medical writing, gifts or other services from Pfizer Inc and Taiho Oncology (both to institution). J.Z.: was an employee of and shareholder in Puma Biotechnology, Inc. D.DiP.: is an employee of and shareholder in Puma Biotechnology, Inc. C.S.: no conflicts declared. S.D.S.: no conflicts declared. M.F.B.: has received research funding from Grail and consulting fees from Eli Lilly and PetDx. L.D.E.: is an employee of and shareholder in Puma Biotechnology, Inc. F.M.-B.: has received research funding from Puma Biotechnology Inc for the manuscript (to institution), research funding from Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, and Taiho Pharmaceutical Co. (all to institution), consulting fees from AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffmann-La Roche Ltd., Genentech Inc., IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, and Zymeworks, an honorarium for speaking engagement from Chugai Biopharmaceuticals, and advisory board membership for Black Diamond, Biovica, Eisai, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis. K.J.: has received research funding from Puma Biotechnology Inc for the manuscript (to institution). D.B.S. has received consulting fees from BridgeBio, Pfizer, Loxo/Lilly Oncology, FORE Therapeutics, Scorpion Therapeutics, and Vividion Therapeutics and owns stock or stock options in Loxo Oncology, Scorpion Therapeutics, and Vividion Therapeutics. GKA-A has received research funding from Puma Biotechnology Inc for the manuscript, institutional research support from Arcus, Agios, AstraZeneca, BioNTech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva, consulting support form Adicet, Alnylam, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Merck, Nerviano, QED, Redhill, Rafael, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva, and a patent (International Patent Application No. PCT/US2014/031545 filed on March 24, 2014, and priority application Serial No.: 61/804,907; Filed: March 25, 2013).